Fundraising Fox

Carol Suh

Investor

Partner at ARCH Venture Partners

San Francisco Bay Area

Writes $50K – $150M checks Β· typically $25M

About

Carol Suh is a Partner at ARCH Venture Partners focused on early-stage biotechnology investments. Her background spans both investing and operations, including co-founding Orbital Therapeutics, an RNA medicines company acquired for $1.5B in 2025, and co-founding Neumora Therapeutics, which went public on NASDAQ. She has also invested in HI-Bio, a clinical-stage immunology company acquired by Biogen in 2024, and serves as a founding board member of the Complex Disorders Alliance.

Experience

  1. ARCH Venture PartnersPartnercurrent2018 β€” present
  2. NeumoraCo-Founder and Chief Strategy Officer2019 β€” 2026San Francisco Bay Area
  3. Orbital TherapeuticsCo-founder, Board Member2022 β€” 2025
  4. HIBioBoard Member2021 β€” 2024
  5. Magenta TherapeuticsBusiness Development and Corporate Strategy Associate; Launch Fellow2016 β€” 2017Cambridge, MA
  6. Trinity PartnersSenior Associate Consultant2015 β€” 2016Waltham, MA
  7. GlaxoSmithKlineR&D Strategy; Innovation Fellow2014Greater Boston

Education

  1. Stanford University Graduate School of BusinessMaster of Business Administration - MBA
  2. Yale UniversityMaster of Philosophy (M.Phil.)
  3. Harvard UniversityBachelor of Arts (B.A.)
  4. Palos Verdes Peninsula High School

Same school

Shared employers

Colleagues at ARCH Venture Partners

Network5

Investors connected to Carol in public investor directories β€” a warm-intro map.